SKB BIO-B (06990) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 950 million, representing a year-on-year decrease of 31.3%. R&D expenses totaled RMB 612 million, down 6.3% compared to the same period last year. Loss attributable to equity shareholders of the company was RMB 145 million, with loss per share of RMB 0.64.
The company announced that it has obtained marketing approvals for sac-TMT (Jiatailai®), Tagolimab (Ketailai®), and Cetuximab N01 (Datailai®), and has commenced their commercialization. Based on the expected approval timeline for various late-stage projects in the pipeline, pending regulatory communications and marketing approvals, the company expects to launch Blidatuzumab (Shutailai®) in the Chinese market in the second half of 2025 and submit an NDA for A400.
Commercial sales in the first half of 2025 reached RMB 309.8 million, with Jiatailai® accounting for 97.6% of sales. Additionally, all accounts receivable from drug sales were collected within the credit period, demonstrating efficient and stable cash flow recovery.
Supported by three proprietary technology platforms for internal development of ADC and novel conjugated drugs, large molecules (monoclonal antibodies and bispecific antibodies), and small molecule drugs, and validated through clinical-stage drug candidates, the company's pipeline demonstrates diversity in drug modalities, mechanisms, and indication coverage, creating synergies across these areas. Notably, the company is one of the pioneers in ADC development, having accumulated over ten years of experience in this field. It is among the first batch of biopharmaceutical companies in China and one of the few globally to establish an internal ADC and novel conjugated drug platform OptiDC™.
The company's cGMP-compliant end-to-end manufacturing capabilities and comprehensive quality management system further support its drug development capabilities. Moreover, leveraging the decades of experience, industry relationships, and extensive network of controlling shareholder Kelun Pharmaceutical, the company is well-positioned to expand its commercialization infrastructure and market channels.